Harel Insurance Investments & Financial Services Ltd. Has $1.61 Million Stake in Medpace Holdings, Inc. (NASDAQ:MEDP)

Harel Insurance Investments & Financial Services Ltd. boosted its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 51,600.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 5,170 shares of the company's stock after buying an additional 5,160 shares during the quarter. Harel Insurance Investments & Financial Services Ltd.'s holdings in Medpace were worth $1,606,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of MEDP. BlackRock Inc. lifted its stake in shares of Medpace by 0.9% during the first quarter. BlackRock Inc. now owns 3,792,694 shares of the company's stock valued at $620,448,000 after buying an additional 35,121 shares during the period. Wasatch Advisors Inc. increased its stake in Medpace by 12.1% in the first quarter. Wasatch Advisors Inc. now owns 2,728,392 shares of the company's stock valued at $446,338,000 after purchasing an additional 294,103 shares during the last quarter. State Street Corp lifted its position in Medpace by 2.5% during the first quarter. State Street Corp now owns 899,855 shares of the company's stock worth $147,207,000 after buying an additional 21,868 shares during the period. Dimensional Fund Advisors LP boosted its stake in Medpace by 1.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 656,864 shares of the company's stock worth $107,456,000 after buying an additional 9,881 shares during the last quarter. Finally, Riverbridge Partners LLC grew its holdings in Medpace by 7.1% in the 4th quarter. Riverbridge Partners LLC now owns 652,384 shares of the company's stock valued at $199,975,000 after buying an additional 43,197 shares during the period. Institutional investors and hedge funds own 77.98% of the company's stock.

Analyst Upgrades and Downgrades

MEDP has been the topic of several research analyst reports. Robert W. Baird raised their target price on shares of Medpace from $312.00 to $408.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 14th. Deutsche Bank Aktiengesellschaft started coverage on shares of Medpace in a report on Monday, March 18th. They issued a "hold" rating and a $395.00 price target on the stock. UBS Group upgraded Medpace from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $282.00 to $452.00 in a report on Thursday, February 15th. Finally, StockNews.com cut Medpace from a "buy" rating to a "hold" rating in a report on Saturday, March 23rd. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $382.00.

Medpace Stock Down 2.0 %

Shares of Medpace stock traded down $7.86 during trading hours on Monday, hitting $387.14. The company's stock had a trading volume of 145,471 shares, compared to its average volume of 240,312. The business has a fifty day moving average of $388.79 and a 200 day moving average of $316.23. Medpace Holdings, Inc. has a 1-year low of $185.43 and a 1-year high of $419.42. The company has a market capitalization of $11.99 billion, a PE ratio of 44.48, a P/E/G ratio of 2.09 and a beta of 1.38.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings results on Monday, February 12th. The company reported $2.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.22 by $0.24. The firm had revenue of $498.40 million during the quarter, compared to the consensus estimate of $498.72 million. Medpace had a return on equity of 63.98% and a net margin of 15.00%. The firm's quarterly revenue was up 26.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.12 EPS. On average, sell-side analysts anticipate that Medpace Holdings, Inc. will post 10.53 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, VP Susan E. Burwig sold 102 shares of the business's stock in a transaction on Friday, March 15th. The shares were sold at an average price of $403.00, for a total transaction of $41,106.00. Following the transaction, the vice president now directly owns 15,181 shares of the company's stock, valued at $6,117,943. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, VP Susan E. Burwig sold 102 shares of Medpace stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $403.00, for a total transaction of $41,106.00. Following the sale, the vice president now directly owns 15,181 shares of the company's stock, valued at $6,117,943. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Medpace Investors, Llc sold 13,988 shares of the stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $386.39, for a total value of $5,404,823.32. Following the completion of the transaction, the insider now directly owns 5,525,959 shares of the company's stock, valued at approximately $2,135,175,298.01. The disclosure for this sale can be found here. Insiders sold a total of 189,340 shares of company stock worth $76,651,647 in the last 90 days. 25.70% of the stock is owned by company insiders.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.